Oncology
Targeted protein degradation and next-generation antibody-drug conjugates in solid tumours.
- Programmes
- 22
- Approved
- 9
Phase III readout · VRD-417
Medicine that holds up
under scrutiny.
For eighty years we have developed medicines for conditions where the evidence has to be unambiguous. Our pipeline spans oncology, immunology, neuroscience and vaccines, in 118 countries.
- $8.4B
- R&D investment, FY2025
- 61
- Programmes in clinical development
- 2
- Medicines approved here
Trial spotlight
HORIZON-3 meets primary endpoint
VRD-417 demonstrated a statistically significant improvement in progression-free survival in advanced renal cell carcinoma.
01 — Development pipeline
61 programmes, from
discovery to registration.
CANDIDATE & INDICATION
PRECLINICAL
PHASE I
PHASE II
PHASE III
PEAK EST.
VRD-417
Advanced renal cell carcinoma
Phase III
$3.1B
VRD-208
HER2-low metastatic breast cancer
Phase II
$2.4B
VRD-931
Moderate-to-severe Crohn's disease
Phase III
$4.0B
VRD-660
Systemic lupus erythematosus
Phase I
$1.2B
VRD-114
Early Alzheimer's disease
Phase II
$5.6B
VRD-372
Drug-resistant focal epilepsy
Phase I
$0.9B
VRD-505
Pan-coronavirus, thermostable mRNA
Phase II
$1.8B
VRD-088
RSV, older adults
Preclinical
$0.7B
Showing 8 of 61programmes · Data as of 30 June 2026
02 — Therapeutic areas
Where our science concentrates
We concentrate on four areas where the biology is understood well enough to act on and the unmet need is large enough to justify the risk.
Immunology
Selective cytokine modulation for inflammatory bowel and rheumatic disease.
- Programmes
- 16
- Approved
- 11
Neuroscience
Disease-modifying approaches to neurodegeneration and refractory epilepsy.
- Programmes
- 13
- Approved
- 5
Vaccines
Thermostable mRNA platforms designed for low-resource distribution networks.
- Programmes
- 10
- Approved
- 17
03 — Performance
Sustained reinvestment in discovery
Research and development spending has grown every year for six years, ahead of revenue growth in four of them. All figures are fictional.
- Net revenue FY2025
- $39.7B
- Core operating margin
- 32.4%
- Free cash flow
- $11.2B
R&D investment vs. net revenue
R&D spend ($B)Net revenue ($B)
04 — Global operations
Supply that reaches the last mile
Manufacturing in eleven countries and a cold chain built for thermostable formats, so that registration in a market translates into availability in it.
- 118
- Countries served
- 3.8B
- Doses shipped, 2025
- 99.4%
- On-time, in-full delivery
- −41%
- Scope 1+2 emissions vs. 2019
06 — Marketed medicines
Approved in the European Union
These medicines hold a current marketing authorisation in your territory. The product information shown is the labelling approved here, and differs from the labelling approved elsewhere.
Emrelimab
Healthcare professionals only
- Market
- European Union
- Job code
- EU-EMR-2026-0143
- Review date
- May 2027
Velorastat
- Market
- European Union
- Job code
- EU-VEL-2026-0088
- Review date
- March 2027
05 — Newsroom
Latest from Veridian
REGULATORY28 AUG 2026
FDA grants Priority Review to VRD-417 in advanced renal carcinoma
PDUFA action date set for 14 February 2027 following HORIZON-3 results.
ACCESS19 AUG 2026
Tiered-pricing agreement extends coverage to 14 additional LMIC markets
Partnership with the Global Fund targets 40 million additional patients by 2029.
R&D04 AUG 2026
Basel discovery centre opens with 600-scientist protein degradation unit
A $1.1B facility consolidating structural biology and computational chemistry.
Work on medicines that matter
1,240 open roles across research, clinical operations, manufacturing and commercial.